Ixazomib citrateProduct ingredient for Ixazomib
- Name
- Ixazomib citrate
- Drug Entry
- Ixazomib
Ixazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,4 it is considered a boronate proteasome inhibitor.1 More than 99% of the drug compound is the R-enantiomer.4
Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.2 It was later approved by Health Canada on August 3, 2016,6 and by the EMA on November 21, 2016.7 It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis.3
- Accession Number
- DBSALT001605
- Structure
Structure for Ixazomib citrate (DBSALT001605)
- Synonyms
- 2,2'-(2-((1R)-1-((N-(2,5-DICHLOROBENZOYL)GLYCYL)AMINO)-3-METHYLBUTYL)-5-OXO-1,3,2-DIOXABOROLANE-4,4-DIYL)DIACETIC ACID / Ixazomib Citrate
- External IDs
- MLN 9708 / MLN-9708 / MLN9708